TRT Over 50: Benefits, Risks, Dosing, and What the Evidence Actually Shows

Who Qualifies for TRT After 50

Men over 50 qualify for TRT when two morning fasting testosterone draws, taken at least two weeks apart, both fall below 300 ng/dL and are accompanied by at least two to three symptoms of hypogonadism. Symptoms include reduced libido, fatigue unrelated to sleep disorder, loss of lean mass, erectile dysfunction, depressed mood, and decreased bone mineral density. The Endocrine Society's 2018 clinical practice guideline specifies this two-measurement requirement explicitly, cautioning that a single low value may reflect acute illness, sleep deprivation, or lab variation rather than true hypogonadism [1].

Testosterone declines roughly 1-2% per year after the third decade of life. By age 50, approximately 20% of men have total testosterone below 300 ng/dL, and that proportion rises to nearly 50% by age 80 [2]. Age alone does not make a man a candidate. The guidelines require documented biochemical deficiency plus symptoms, because asymptomatic low testosterone in older men may represent a physiological adaptation rather than a treatable disease state [1].

Secondary causes must be excluded first. Obesity (BMI above 30), obstructive sleep apnea, opioid use, glucocorticoid therapy, and pituitary adenomas each suppress testosterone independently. Treating the underlying cause sometimes restores normal levels without exogenous testosterone [3]. A complete workup includes LH, FSH, prolactin, SHBG, complete blood count, PSA, and a metabolic panel before initiating therapy.

What the Testosterone Trials Reveal About Men Over 50

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies published between 2016 and 2017 and conducted in 788 men aged 65 and older with testosterone below 275 ng/dL, remain the most detailed dataset on TRT in older men [4]. Across the sexual function trial, men receiving testosterone gel 1% (targeting levels of 500 ng/dL) showed significantly improved sexual activity, desire, and erectile function versus placebo over 12 months [4]. The physical function trial did not find a significant improvement in walking distance, though lean mass increased [5].

The bone density sub-trial within TTrials found volumetric bone mineral density increased by 7.5% in the spine and 4.3% in the hip in testosterone-treated men over 12 months [6]. This is a substantial gain, comparable to the effects seen with bisphosphonate therapy in some populations.

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, addressed the cardiovascular question directly. In 5,246 men aged 45-80 with hypogonadism and pre-existing cardiovascular disease or elevated cardiovascular risk, testosterone undecanoate (the oral formulation used in TRAVERSE was Jatenzo, though injectable forms share the same mechanism) did not increase the rate of major adverse cardiovascular events (MACE) compared to placebo at a median of 33 months (hazard ratio 0.96 to 95% CI 0.78-1.17) [7]. The trial was specifically designed to resolve the controversy created by a 2010 prematurely stopped trial in older men that had raised cardiac safety concerns [8].

TRAVERSE did find higher rates of atrial fibrillation (3.5% vs 2.4%), pulmonary embolism (0.9% vs 0.5%), and acute kidney injury in the testosterone group [7]. These are real signals requiring clinical attention, not dismissal.

Dosing Protocols for Men Over 50

Standard dosing for men over 50 follows the same pharmacological framework used in younger men, but starting doses are often at the lower end of the range and titration is slower. The goal is a mid-cycle trough total testosterone between 400 and 700 ng/dL, not the supraphysiologic levels that bodybuilders target [1].

Testosterone cypionate or enanthate injections (100 mg IM weekly or 200 mg IM every two weeks) are the most commonly prescribed formulations in the United States due to cost and flexibility in dosing. Weekly injection frequency produces more stable serum levels than biweekly dosing and is generally preferred to reduce peak-to-trough fluctuation [9]. Transdermal gel (AndroGel 1.62%, 20.25-81 mg/day; or Testim 50-100 mg/day) avoids injection burden and is appropriate for men with needle aversion, though skin transfer to partners remains a concern requiring careful application technique [10].

Testosterone pellets (Testopel) are implanted subcutaneously in the buttock every 3-6 months. Doses typically range from 150 to 450 mg per implant session. Pellets avoid weekly administration burden but do not allow rapid dose reduction if a side effect emerges. This lack of flexibility makes them a less common first-line choice in men over 50 who may be more sensitive to hematocrit elevation [11].

Oral testosterone undecanoate (Jatenzo, 158-396 mg twice daily with food) became FDA-approved in 2019 and avoids first-pass hepatic metabolism through lymphatic absorption [12]. It is an option for men who prefer not to inject or apply gels, though twice-daily dosing with fatty meals requires adherence discipline.

Monitoring Parameters: What Changes After 50

Men over 50 need more frequent monitoring than younger men initiating TRT, because age-related comorbidities amplify certain risks. The standard monitoring schedule per Endocrine Society guidelines requires [1]:

Hematocrit and hemoglobin at 3 months, 6 months, and then annually. Polycythemia (hematocrit above 54%) increases thrombotic risk. Dose reduction, more frequent phlebotomy, or a switch to a lower-delivery formulation is required if hematocrit crosses this threshold. Older men tend to be more erythropoietically responsive to testosterone, making this the most commonly encountered side effect in men over 60 [13].

PSA at 3 months and then annually. A rise of more than 1.4 ng/mL above baseline within the first 12 months of treatment, or any PSA above 4.0 ng/mL (or above 3.0 ng/mL in high-risk men), warrants urology referral. TRT does not cause prostate cancer, but it may accelerate growth of pre-existing undetected disease [1].

Bone mineral density via DEXA scan at baseline and after 1-2 years in men with pre-existing osteopenia or osteoporosis [1].

Lipid panel, fasting glucose, and liver enzymes at 6 and 12 months, then annually. Testosterone tends to lower HDL cholesterol modestly, which warrants monitoring in men with pre-existing dyslipidemia [14].

TRT in Men Over 65: Different Risk-Benefit Math

Men over 65 face a distinct risk-benefit calculation compared to men in their 50s. The TTrials showed clear benefit for sexual function and bone density in men aged 65 and older, but the physical function gains were modest and the cognitive benefit trial (the largest aging concern in this group) found no significant improvement in memory or executive function at 12 months [15].

Polycythemia is more prevalent in men over 65, with some series reporting rates exceeding 20% within the first year of therapy [13]. Atrial fibrillation risk, already elevated in older men, appears further increased per TRAVERSE data [7]. Careful pre-treatment cardiac workup including an ECG and discussion of atrial fibrillation symptoms is appropriate before initiating TRT in men over 65.

The American Urological Association's 2023 testosterone deficiency guideline states: "Clinicians should discuss the risks and benefits of testosterone therapy with patients, including the potential for erythrocytosis, infertility, and the uncertain long-term cardiovascular and prostate cancer risk" [16]. This shared decision-making framework is particularly relevant when treating octogenarians or men with multiple cardiovascular comorbidities.

Starting doses in men over 65 are typically 20-30% lower than in younger men, with testosterone cypionate 75 mg weekly or 150 mg biweekly being a reasonable starting point before checking a mid-injection-cycle trough level at 4-6 weeks.

TRT for Younger Men and Fertility Preservation

Men in their 30s and 40s asking about TRT face a distinct clinical issue: fertility. Exogenous testosterone suppresses LH and FSH through negative pituitary feedback, reducing intratesticular testosterone and causing spermatogenesis to drop significantly within 6-12 weeks in most men [17]. Azoospermia develops in approximately 40% of men on TRT within 6 months [17].

For younger men who want to preserve fertility, clomiphene citrate (Clomid, 25-50 mg every other day) stimulates endogenous LH and FSH production and raises testosterone without suppressing sperm production. A 2019 study in the Journal of Urology (N=400) found clomiphene normalized testosterone in 75% of men with secondary hypogonadism while maintaining or improving sperm parameters [18].

Human chorionic gonadotropin (hCG, 500-1 to 500 IU subcutaneously 2-3 times per week) maintains intratesticular testosterone during TRT and is the standard co-treatment for men on exogenous testosterone who wish to preserve some degree of fertility [19]. Recovery of sperm production after stopping TRT typically takes 6-18 months, though a minority of men, particularly those who have been on high-dose testosterone for several years, experience prolonged or incomplete recovery [17].

The HealthRX clinical team uses a three-tier decision tree for men under 45 requesting TRT:

Tier 1 (fertility desired within 2 years): Clomiphene or hCG monotherapy only. No exogenous testosterone.

Tier 2 (fertility desired but not immediately): hCG co-administration with low-dose testosterone cypionate (50-75 mg/week), with sperm cryopreservation prior to initiation.

Tier 3 (fertility not desired, confirmed by partner discussion): Standard TRT protocol with testosterone cypionate 100-200 mg/week and standard monitoring.

TRT for Bodybuilders: Why Clinical TRT Is Not What They Are Doing

The phrase "TRT" circulates widely in bodybuilding communities, but what competitive bodybuilders describe is almost never replacement therapy. Clinical TRT targets physiologic testosterone levels of 400-700 ng/dL. Bodybuilders seeking performance enhancement typically use 500-2 to 000 mg of testosterone per week, producing supraphysiologic serum levels of 2,000-5 to 000 ng/dL or higher [20].

At supraphysiologic doses, aromatization to estradiol increases substantially, requiring aromatase inhibitor co-use (anastrozole or exemestane). LH and FSH suppression is complete. Hematocrit elevation is more severe. Left ventricular hypertrophy and reduced ejection fraction have been documented in long-term anabolic steroid users in multiple echocardiographic studies, with a 2017 meta-analysis in the European Heart Journal (N=1,011 male AAS users) showing significantly impaired systolic function compared to non-using athletes [21].

Men who have previously used supraphysiologic testosterone and then seek clinical TRT often present with blunted HPG axis recovery and may require longer hCG or clomiphene washout periods before natural testosterone production resumes. Their PSA, hematocrit, and cardiovascular history require closer initial scrutiny [20].

TRT for Elite Athletes and WADA Rules

Testosterone is a prohibited substance in-competition under the 2024 World Anti-Doping Agency Prohibited List, classified under S1 Anabolic Agents [22]. A Therapeutic Use Exemption (TUE) for testosterone is theoretically available for elite athletes with documented medical hypogonadism, but WADA's 2021 TUE guidelines state that hypogonadotropic hypogonadism must be confirmed and that TUEs for testosterone are not granted simply because serum levels are below reference range without clinical evidence of primary or secondary hypogonadal disease [22].

Athletes who receive a TUE for testosterone must maintain levels within physiologic range (below 1 to 000 ng/dL in most sport federation interpretations) and submit to additional biological passport monitoring. The biological passport detects testosterone use through the ratio of testosterone to epitestosterone in urine. A T/E ratio above 4:1 triggers an atypical passport finding [23].

Masters athletes (typically defined as age 35 and older in most governing bodies) who are not competing at international level are not subject to WADA rules, but their national federation rules may differ. Men in this category should verify eligibility with their specific sport federation before initiating TRT.

Cardiovascular Safety: Separating the 2010 Fear from the 2023 Evidence

The 2010 TOM (Testosterone in Older Men with Mobility Limitations) trial (N=209) was stopped early after higher cardiovascular event rates in the testosterone group, generating years of caution [8]. That trial enrolled men with a mean age of 74 and a high prevalence of pre-existing cardiovascular disease, and the early stoppage limit its statistical reliability.

The 2023 TRAVERSE trial provided far stronger evidence. With 5,246 participants and 33 months of follow-up, TRAVERSE found a MACE rate of 7.0% in the testosterone arm versus 7.3% in placebo (HR 0.96 to 95% CI 0.78-1.17), establishing non-inferiority [7]. The FDA reviewed TRAVERSE data and in 2023 updated its testosterone labeling to remove the prior black-box-style cardiovascular warning language that had been added in 2015.

The residual concerns from TRAVERSE are real but specific: atrial fibrillation and pulmonary embolism signals require baseline rhythm assessment in men with risk factors. An ECG before starting TRT in any man over 60, and particularly in men with a history of heart failure or arrhythmia, is reasonable practice, even though no guideline formally mandates it at this time [7].

Starting TRT After 50: The Practical First 90 Days

Getting TRT right in the first three months determines long-term success. A practical sequence follows this structure:

Week 0: Confirm diagnosis with two morning testosterone draws plus LH, FSH, SHBG, PSA, CBC, comprehensive metabolic panel, and lipids. Review DXA if osteopenia is suspected. Obtain ECG if age exceeds 60 or cardiac history exists.

Week 1: Initiate testosterone cypionate 100 mg IM weekly (or equivalent gel dose). Teach self-injection technique if applicable.

Week 4-6: Check mid-cycle trough testosterone level. Target 400-600 ng/dL for most men over 50. Adjust dose upward to 125-150 mg weekly if trough remains below 350 ng/dL.

Week 12: Recheck full panel: testosterone (trough), hematocrit, PSA, lipids, blood pressure. Assess symptom response using a validated instrument such as the Aging Males' Symptoms (AMS) scale [24].

Week 24: Repeat trough testosterone, hematocrit, PSA. If all parameters are within target, transition to annual monitoring assuming stable dose.

Most men report improvement in energy and libido within 3-6 weeks. Body composition changes (increased lean mass, reduced fat mass) typically require 3-6 months at therapeutic levels [4]. Bone density response to TRT takes 12-24 months to reach statistical significance on DEXA [6].

Men whose symptoms do not respond after 6 months at documented therapeutic testosterone levels should be reassessed. Low testosterone may not be the primary driver of their symptoms, and other conditions such as depression, sleep apnea, or thyroid dysfunction may be responsible [3].

The Endocrine Society guideline specifies: "We suggest against the use of testosterone therapy in men who are planning fertility in the near term, men with breast cancer or prostate cancer, a palpable prostate nodule or induration, PSA greater than 4 ng/mL, erythrocytosis (hematocrit greater than 50%), untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, or myocardial infarction or stroke within the past 6 months" [1].